California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
REDWOOD CITY, Calif., Nov. 04, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective November 4, 2016, the compensation committee of the company’s board of directors granted 7 new employees options to purchase an aggregate of 83,000 shares of the company’s common stock with a per share exercise price of $28.15, the closing trading price on the grant date. In addition, 75,000 shares of stock were granted to a Vice President, Marketing new hire and 45,000 shares of stock were granted to a Vice President, Product Development new hire under the same terms. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O’Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
